[go: up one dir, main page]

HUP0301740A2 - Emlőrák kezelésére és diagnosztizálására szolgáló készítmények és eljárások - Google Patents

Emlőrák kezelésére és diagnosztizálására szolgáló készítmények és eljárások

Info

Publication number
HUP0301740A2
HUP0301740A2 HU0301740A HUP0301740A HUP0301740A2 HU P0301740 A2 HUP0301740 A2 HU P0301740A2 HU 0301740 A HU0301740 A HU 0301740A HU P0301740 A HUP0301740 A HU P0301740A HU P0301740 A2 HUP0301740 A2 HU P0301740A2
Authority
HU
Hungary
Prior art keywords
polypeptides
breast cancer
preparations
subject
cells
Prior art date
Application number
HU0301740A
Other languages
English (en)
Inventor
Davin C. Dillon
Susan L. Harlocker
William T. Hepler
Yuqiu Jiang
Jennifer L. Mitcham
Jiangchun Xu
Original Assignee
Corixa Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/551,621 external-priority patent/US6844325B2/en
Priority claimed from US09/604,287 external-priority patent/US6586572B2/en
Application filed by Corixa Corporation filed Critical Corixa Corporation
Publication of HUP0301740A2 publication Critical patent/HUP0301740A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/924—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis using nanostructure as support of dna analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A találmány tárgyát emlődaganat-protein vagy variánsa legalább egyimmunogén részletét tartalmazó izolált polipeptidek, a polipeptidekettartalmazó fúziós proteinek és a polipeptidekre specifikusellenanyagok, a polipeptideket kódoló izolált polinukleotidok, apolinukleotidokat tartalmazó expressziós vektorok, valamint azexpressziós vektorokkal transzfektált gazdasejtek képezik. A találmánytárgyát képezik továbbá a polipeptideket, polinukleotidokat, fúziósproteineket, valamint monoklonális ellenanyagokat tartalmazó, emlőrákpáciensbeli kialakulásának megakadályozására és kezelésére szolgálógyógyászati készítmények és immunogén készítmények. A találmánytárgyát képezik továbbá emlőrák páciensbeli jelenlétének kimutatásáraés előrehaladásának monitorozására szolgáló eljárások és diagnosztikaireagenskészletek. A találmány tárgyát képezik továbbá az említettpolipeptidekkel vagy polinukleotidokkal történt inkubálássalelőállított proliferált T-sejtek és antigénbemutató sejtek, az azokattartalmazó készítmények, valamint a T-sejtek, antigénbemutató sejtekés készítmények emlőrák gyógykezelésére történő alkalmazása. Ó
HU0301740A 2000-04-17 2001-04-12 Emlőrák kezelésére és diagnosztizálására szolgáló készítmények és eljárások HUP0301740A2 (hu)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/551,621 US6844325B2 (en) 1998-12-28 2000-04-17 Compositions for the treatment and diagnosis of breast cancer and methods for their use
US09/590,751 US6756477B1 (en) 1998-12-28 2000-06-08 Compositions and methods for the therapy and diagnosis of breast cancer
US09/604,287 US6586572B2 (en) 1998-12-28 2000-06-22 Compositions and methods for the therapy and diagnosis of breast cancer
US09/620,405 US6528054B1 (en) 1998-12-28 2000-07-20 Compositions and methods for the therapy and diagnosis of breast cancer
PCT/US2001/012164 WO2001079286A2 (en) 2000-04-17 2001-04-12 Compositions and methods for the therapy and diagnosis of breast cancer

Publications (1)

Publication Number Publication Date
HUP0301740A2 true HUP0301740A2 (hu) 2004-06-28

Family

ID=27504757

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301740A HUP0301740A2 (hu) 2000-04-17 2001-04-12 Emlőrák kezelésére és diagnosztizálására szolgáló készítmények és eljárások

Country Status (14)

Country Link
US (1) US6528054B1 (hu)
EP (1) EP1299417A2 (hu)
JP (1) JP5053497B2 (hu)
CN (1) CN1646563A (hu)
AU (1) AU2001255369A1 (hu)
BR (1) BR0110091A (hu)
CA (1) CA2406213A1 (hu)
HU (1) HUP0301740A2 (hu)
MX (1) MXPA02010244A (hu)
NO (1) NO20024972L (hu)
NZ (1) NZ521865A (hu)
PL (1) PL365244A1 (hu)
RU (1) RU2344831C2 (hu)
WO (1) WO2001079286A2 (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033230A1 (en) * 1997-12-24 2004-02-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7414112B2 (en) * 1998-10-08 2008-08-19 Genentech, Inc. Antibodies to PRO1550 polypeptides
US7598226B2 (en) * 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6969518B2 (en) * 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
CA2392510A1 (en) * 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US7354992B2 (en) * 1999-11-30 2008-04-08 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
GB0222787D0 (en) * 2002-10-02 2002-11-06 Univ Liverpool Metastasis inducing compounds
CA2511858A1 (en) 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
US20070178532A1 (en) * 2003-03-24 2007-08-02 The Gov.Of The Us As Represented By The Secretary Identification, quantification, and characterization of t cells and t cell antigens
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
TW200607816A (en) 2004-06-25 2006-03-01 Takeda Pharmaceuticals Co Metastin derivatives and use thereof
KR101772375B1 (ko) * 2005-09-07 2017-08-29 신라젠(주) Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
US20100029504A1 (en) * 2007-01-16 2010-02-04 Phigenix, Inc. Detecting pax2 for the diagnosis of breast cancer
TWI386417B (zh) 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
WO2008039482A2 (en) * 2006-09-26 2008-04-03 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
CN101974088B (zh) * 2010-11-03 2014-04-02 中国人民解放军军事医学科学院基础医学研究所 乳腺珠蛋白单克隆抗体及其在乳腺癌诊断中的应用
WO2013016126A1 (en) 2011-07-22 2013-01-31 The General Hospital Corporation Therapeutic nanoparticles and methods of use thereof
JP2016214239A (ja) * 2015-05-15 2016-12-22 国立大学法人高知大学 膵がんマーカー
PT3383425T (pt) * 2015-12-04 2020-10-07 Boehringer Ingelheim Int Polipéptidos biparatópicos que antagonizam a sinalização wnt em células tumorais
WO2017120274A1 (en) * 2016-01-08 2017-07-13 Temple University Of The Commonwealth System Of Higher Education Stabilized peptide fragments from protocadherin fat1 as cancer biomarkers
CN111315759B (zh) 2017-10-12 2023-10-13 E&S医疗保健有限公司 硫氧还蛋白1表位及与其特异性结合的单克隆抗体
TWI709188B (zh) 2018-09-27 2020-11-01 財團法人工業技術研究院 基於機率融合的分類器、分類方法及分類系統
RU2736163C1 (ru) * 2019-05-29 2020-11-12 Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации Даггосмедуниверситет Способ интраоперационной диагностики рака молочной железы
CN112724233B (zh) * 2019-10-28 2023-09-26 中国医学科学院药物研究所 一种角蛋白bd-13、制法和其药物组合物与用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2613988A (en) 1988-01-04 1989-08-01 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
WO1991016116A1 (en) 1990-04-23 1991-10-31 Cellpro Incorporated Immunoselection device and method
CA2094258A1 (en) 1990-10-18 1992-04-19 Dale Kalamasz An apparatus and method for separating particles using a pliable vessel
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
EP1505159B1 (en) 1995-03-17 2008-05-28 John Wayne Cancer Institute Detection of breast metastases with a multiple marker assay
US5922836A (en) 1995-05-31 1999-07-13 Washington University Mammaglobin antigens
US5668267A (en) 1995-05-31 1997-09-16 Washington University Polynucleotides encoding mammaglobin, a mammary-specific breast cancer protein
US5985564A (en) * 1995-08-16 1999-11-16 President And Fellows Of Harvard College Assay for identifying agents that inhibit chromosome non-disjunction
US5986170A (en) 1995-11-13 1999-11-16 Corixa Corporation Murine model for human carcinoma
US5891857A (en) 1996-02-20 1999-04-06 Vanderbilt University Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
WO1998021331A1 (en) 1996-11-12 1998-05-22 Incyte Pharmaceuticals, Inc. Human breast tumor-specific proteins
CA2280229A1 (en) 1997-02-03 1998-08-06 Human Genome Sciences, Inc. Breast cancer specific gene 1
WO1998054963A2 (en) 1997-06-06 1998-12-10 Human Genome Sciences, Inc. 207 human secreted proteins
WO1999009155A1 (en) 1997-08-19 1999-02-25 Human Genome Sciences, Inc. 70 human secreted proteins
EP1042360A2 (en) * 1997-12-24 2000-10-11 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
ES2277432T3 (es) * 1998-03-18 2007-07-01 Corixa Corporation Compuestos y metodos para terapia y diagnosis de cancer de pulmon.
EP1870466A3 (en) * 1998-07-14 2008-03-19 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
WO2000008210A1 (en) 1998-08-04 2000-02-17 Diadexus Llc A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2000043420A1 (en) 1999-01-21 2000-07-27 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
EP1259812A2 (en) 1999-05-28 2002-11-27 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
CA2390802A1 (en) 1999-11-23 2001-05-31 Diadexus, Inc. A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
JP5640237B2 (ja) 1999-11-30 2014-12-17 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ リミテッド 癌関連抗原をコードする単離された核酸分子、その抗原そのものおよびその使用

Also Published As

Publication number Publication date
BR0110091A (pt) 2004-02-25
AU2001255369A1 (en) 2001-10-30
RU2002130715A (ru) 2004-03-27
JP5053497B2 (ja) 2012-10-17
WO2001079286A3 (en) 2003-01-30
PL365244A1 (en) 2004-12-27
MXPA02010244A (es) 2003-05-23
CN1646563A (zh) 2005-07-27
JP2004520802A (ja) 2004-07-15
RU2344831C2 (ru) 2009-01-27
NO20024972D0 (no) 2002-10-16
CA2406213A1 (en) 2001-10-25
EP1299417A2 (en) 2003-04-09
NO20024972L (no) 2002-12-11
US6528054B1 (en) 2003-03-04
WO2001079286A2 (en) 2001-10-25
NZ521865A (en) 2004-07-30

Similar Documents

Publication Publication Date Title
HUP0301740A2 (hu) Emlőrák kezelésére és diagnosztizálására szolgáló készítmények és eljárások
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
PT1349870E (pt) Composições para a terapêutica e diagnóstico do cancro do ovário
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
NO20004631L (no) Forbindelser og fremgangsmÕter for terapi og diagnose av lungekreft
HUP0103598A2 (hu) Készítmények és eljárások WT1-specifikus immunterápiás alkalmazásra
WO2002054081A3 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
IL145535A0 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
WO2001075171A3 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
ATE486938T1 (de) C-typ-lektin-transmembran-antigen, das in menschlichem prostatakrebs exprimiert wird, und verwendungen dieses antigens
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
HUP9903378A2 (hu) Az autoimmun betegségek immunterápiájában felhasználható autoantigének és ezekkel szerkezetileg rokon fehérjék
BR9808509A (pt) Composições e métodos para o tratamento e diagnóstico do câncer de mama
EP1767636A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
HUP0102479A2 (hu) Neisseria meningitidis-ből származó BASBO29-polinukleotid(ok) és polipeptidek
WO2002088750A3 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
HUP0300054A1 (hu) Daganatspecifikus állati fehérjék
EA201591219A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
ATE514780T1 (de) Zusammensetzungen für die therapie und diagnose von brustkrebs und verwendung davon
BR0009573A (pt) Composições e métodos para o tratamento e diagnose do câncer de mama
HUP0102853A1 (hu) Moraxella catarrhalis-ból származó vegyületek

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees